Phio Pharmaceuticals shares rise 11.48% intraday after positive 1b trial results for PH-762, showing 85% pathological response rate in highest dose group.
ByAinvest
Friday, Feb 13, 2026 10:05 am ET1min read
PHIO--
Phio Pharmaceuticals surged 11.48% intraday as the clinical-stage siRNA bio-pharma company reported positive phase 1b clinical trial results for its lead candidate PH-762, targeting skin cancer. The trial, announced on February 10, 2026, showed no serious adverse events or dose-limiting toxicities, with an 85% pathological response rate in the highest dose group of 22 patients. The company develops cancer therapies using its INTASYL gene-silencing platform, focusing on advancing end-to-end siRNA-based treatments for oncology indications.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet